AstraZeneca and lung cancer: the pharmaphorum podcast

This episode of the pharmaphorum podcast focuses on lung cancer, with AstraZeneca’s VP, global franchise head, Tagrisso TDR (Tumour Drivers and Resistance) Patrick Connor explaining why the

AZ’s Forxiga gets heart claim data on its EU label

Lung cancer’s patient information gap: the pharmaphorum podc...

For episode 13 of the pharmaphorum podcast podcast I went to AstraZeneca’s London base to meet Paul Naish, who’s the company’s director of oncology advocacy and government affairs, to talk

EU clears GSK’s asthma drug Nucala in patient-friendly forma...

NICE expands funding for AstraZeneca's high potassium drug

NICE has recommended extended funding on the NHS for AstraZeneca’s high potassium drug Lokelma in final draft guidance.

Exclusive Interview with AstraZeneca’s Former VP, Medical Ev...

Ahead of the 7th Annual IMPACCT: Real World Evidence, Sandy Leonard, former VP, Medical Evidence & Observational Research at AstraZeneca has taken some time